An Open-Label, Multiple-Dose Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
Latest Information Update: 18 Aug 2021
At a glance
- Drugs DWC-202005 (Primary) ; Fexuprazan (Primary)
- Indications Gastro-oesophageal reflux; Peptic ulcer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 13 Aug 2021 Status changed from not yet recruiting to completed.
- 06 Apr 2020 New trial record